Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

NCT00679133 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies

Interventions

DRUG: MGCD265

Sponsor

Mirati Therapeutics Inc.